Stock listing

gettex:9HA Elicio Therapeutics, Inc. Aktie

German listing (gettex) of Elicio Therapeutics, Inc. · home listing NASDAQ:ELTX

Follow Elicio Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ELTX

$1.55 USD -0.01 (-0.6%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ELTX

Since Jul 6, 2026 -53.0% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$1.44 – $1.60 USDOct 19, 2026
Volume
298,127 sharesOct 19, 2026
Market value
$41.99M USDAt the close on Oct 19, 2026 · price × 27.09M shares outstanding
Elicio Therapeutics, Inc. logo
Ticker
gettex:9HA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Sep 24, 2026

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Aug 31, 2026

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Aug 24, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 13, 2026

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Aug 10, 2026

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Jul 6, 2026

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Jul 2, 2026

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Jun 29, 2026

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Jun 17, 2026

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Jun 15, 2026

All Elicio Therapeutics, Inc. news

Financings

  • Registered direct offering of shares of common stock

    Aug 13, 2026

    Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1

    Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.

    Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline

    Closed Jul 6, 2026 · Closed Aug 13, 2026

Read by 6ix AI from the company's releases

Decks

Elicio Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 33 in all · newest Sep 24, 2026 · oldest 2025
Decks
11 decks · latest September 2026

Where Elicio Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ELTX · Home listingNASDAQUnited StatesUSD
LS Exchange:A3CY4JLS ExchangeGermanyEUR
BOATS:ELTXBOATSUnited StatesUSD
Lang & Schwarz:A3CY4JLang & SchwarzGermanyEUR
gettex:9HA · This pagegettexGermanyEUR
Dusseldorf:9HADusseldorfGermanyEUR
Frankfurt:9HAFrankfurtGermanyEUR
Munich:9HAMunichGermanyEUR
Tradegate:9HATradegateGermanyEUR

Log in to ask 6ix AI your own questions about Elicio Therapeutics, Inc.